摘要
肿瘤免疫疗法在当前癌症治疗领域中愈来愈受瞩目,相关研究也层出不穷。对于非小细胞肺癌(non-small cell lung cancer,NSCLC)患者来说,近些年来,以程序性死亡受体1(programmed cell death 1,PD-1)/程序性死亡配体1(programmed cell death ligand 1,PD-L1)免疫抑制剂为代表的免疫检查点抑制剂(immunecheckpoint inhibitors,ICIs)已经成为治疗恶性肿瘤的一种最具前景的治疗方案。免疫检查点阻断治疗包括抗细胞毒T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen 4,CTLA-4)单抗、抗PD-1单抗和抗PD-L1单抗,其中最被人熟知的为PD-L1免疫疗法。目前ICIs在临床治疗中取得了很不错的治疗效果,但有效率较低,因此我们希望获得更高的治疗有效率。近几年外泌体PD-L1在NSCLC免疫治疗中发挥了重要作用。本文就肿瘤外泌体PD-L1蛋白对肿瘤微环境的影响、预测免疫治疗效果以及作为NSCLC免疫治疗的新型治疗策略作一综述。
Cancer immunotherapy is increasingly popular in the field of cancer treatment,and related research is emerging.For patients with non-small cell lung cancer(NSCLC),in recent years,immune checkpoint inhibitors(ICIs)represented by programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1)immunosuppressants,have become one of the most promising treatments for malignant tumors.Immune checkpoint blockade therapy includes anti-cytotoxic T lymphocyte-associated antigen 4(CTLA-4)mAb,anti-PD-1 mAb and anti-PD-L1 mAb,with the best-known number of PD-L1 immunotherapy.At present,ICIs have achieved very good therapeutic results in clinical treatment,but with less effective efficiency,so we hope to obtain higher therapeutic efficiency.In recent years,exosomal PD-L1 has played an important role in the progress of immunotherapy for NSCLC.This paper reviews the effects of tumor exosomal PD-L1 protein on the tumor micro environment,the effect prediction of immunotherapy,and as novel therapeutic strategies for immunotherapy in NSCLC.
作者
王娜
宋霞
Na WANG;Xia SONG(The Second Clinical Medical College of Shanxi Medical University,Taiyuan 030000,China;The Second Department of Respiratory,Shanxi Provincial Cancer Hospital,Taiyuan 030000,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2022年第9期689-695,共7页
Chinese Journal of Lung Cancer
作者简介
通讯作者:宋霞,E-mail:songxia76@hotmail.com。
